News

The FDA cleared abivertinib to be investigated in a phase 2 clinical trial for the treatment of hospitalized patients with moderate to severe COVID-19.

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the data from the MANIFEST trial, which evaluated the use of CPI-0610 as treatment of patients with myelofibrosis.

In an interview with Targeted Oncology, Ping Chi, MD medical oncologist, Geoffrey Beene Junior Faculty chair, Memorial Sloan Kettering Cancer Center, discussed the phase 2 study of binimetinib in combination with imatinib in patients with untreated advanced GIST.

“Accurately identifying patients with high-grade UTUC is critical, as the disease progression can be deadly and the standard treatment – removal of ureter and kidney – leads to major morbidity."

The FDA has accepted the supplemental New Drug Application seeking approval of selinexor as treatment of patients with multiple myeloma following at least 1 prior line of therapy.

Lenvatinib may benefit patients with advanced hepatocellular carcinoma with second- or later-line therapies and a high burden of intrahepatic lesions.

A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the current treatment landscape for acute myeloid leukemia and how he goes about sequencing the available agents when he treats patients in clinic.

Targeted Oncology reviews trending news online for the week of July 17, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

Enzastaurin, a first-in-class small molecule, has been granted a Fast Track designation by the FDA for the potential treatment of patients with newly diagnosed glioblastoma.

The phase 2 basket arm trial of IDE196 in patients with solid tumors harboring GNAQ or GNA11 hotspot mutations has met its clinical protocol criteria for cohort expansion.

A nationwide group of clinical investigators teamed up to explore options on how to manage patients with locally advanced non-small cell lung cancer in a multidisciplinary setting during the ongoing pandemic of coronavirus disease 2019.

“The rationale behind the use of duvelisib is that the drug may be able to calm the systemic inflammation that exacerbates COVID-19-associated pneumonia and acute respiratory distress syndrome."

In an interview with Targeted Oncology, Alfonso E. Bencomo-Alvarez, PhD, discussed his research surrounding disparities in leukemias within the Hispanic community, particularly among the Hispanic population living at the border of Texas, in El Paso, and Mexico.

Once the impact of COVID-19 begins to minimize and activities settle into a “new normal,” efforts to expand precision medicine across many diseases will resume.

In an interview with Targeted Oncology, A. Oliver Sartor, MD, discussed the findings for subsequent 177Lu-PSMA following Radium-223 as treatment of patients with metastatic castration-resistant prostate cancer, as well as the next steps for this research.

The FDA has granted an Orphan Drug designation to APG-2575 for the treatment of patients with Waldenström macroglobulinemia.

“In this single-arm, phase 2 study, the combination of ofatumumab with the hyper-CVAD regimen resulted in a high proportion of adult patients with Ph-negative CD20- positive B-cell acute lymphoblastic leukemia having durable remission and long-term survival…"

The first randomized study of an ATR inhibitor in any malignancy demonstrated the benefit of berzosertib added to gemcitabine as treatment of patients with platinum-resistant high-grade serous ovarian cancer, according to a recently published study.

The national RESPOND study is looking to determine potential underlying factors for the increased burden among African American males compared with American men of European descent and has identified novel variations among the African American population; however, an analysis from the study concluded that genomic alterations in known therapeutic targets show similar frequencies between the 2 racial groups.

“We are pleased the committee recognised the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options."

In an interview with Targeted Oncology, Thomas Cluzeau, MD, PhD, discussed the findings from the phase 2 study of azacitidine plus APR-246 as treatment of patients with TP53-mutant myelodysplastics syndrome and acute myeloid leukemia. He also highlighted the next steps for this treatment regimen.

In a single-arm phase 2 clinical trial, pyrotinib had promising antitumor activity as treatment of patients with HER2-positive non–small cell lung cancer.

The independent Data Monitoring Committee recommended stopping the global phase 3 OPTIMA clinical trial evaluating the combination of ThermoDox with radiofrequency ablation in hepatocellular carcinoma or primary liver cancer.

In an interview with Targeted Oncology, Balazs Halmos, MD, MS, discussed the current treatment landscape of EGFR-mutant NSCLC and how this space is evolving based on recent clinical trials.

In an interview with Targeted Oncology, Petros Grivas, MD, PhD, discussed the findings from the phase 3 JAVELIN Bladder 100 study, which evaluated the addition of avelumab to best supportive care in patients with locally advanced, unresectable or metastatic urothelial cancer.

The phase 3 IMagyn500 clinical trial failed to meet its primary end point of progression-free survival with the addition of atezolizumab to bevacizumab plus paclitaxel and carboplatin chemotherapy in patients with newly diagnosed advanced ovarian cancer.

A post-hoc analysis of the phase III ZETA trial shows that vandetanib improved PFS in medullary thyroid cancer.